Envista Holdings Corp.

As of September 12, 2025, Envista Holdings Corp. has a mildly bullish technical trend, supported by positive MACD and Bollinger Bands, but caution is advised due to a mildly bearish OBV and underperformance compared to the S&P 500.

As of August 7, 2025, Envista Holdings Corp. is considered undervalued with a favorable valuation grade shift, despite its recent stock performance lagging behind the S&P 500, showing a year-to-date return of 9.02% compared to the index's 12.22%.

As of February 7, 2024, Envista Holdings Corp. is considered overvalued and risky, with a high P/E ratio of 73, poor financial metrics like a ROCE of 4.03% and ROE of 1.44%, and a significant underperformance compared to the S&P 500, indicating concerns about its financial health and market position.

As of June 18, 2025, Envista Holdings Corp. shows a mildly bullish trend supported by weekly and monthly MACD and KST indicators, despite some mixed signals from daily moving averages and Bollinger Bands.

As of March 2022, the management team of Envista Holdings Corp. includes Mr. Scott Huennekens (Independent Chairman), Mr. Amir Aghdaei (CEO), and several independent directors: Mr. Daniel Raskas, Ms. Wendy Carruthers, Mr. Kieran Gallahue, Mr. Vivek Jain, and Ms. Gayle Sheppard. This team provides governance and strategic direction for the company.

Envista Holdings Corporation is a small-cap dental products company in the Pharmaceuticals & Biotechnology industry, with net sales of $617 million and a market cap of approximately $3.12 billion as of March 2025. Key financial metrics include a P/E ratio of 73.00 and a return on equity of 1.44%.

As of Jun 18, Envista Holdings Corp. has a market capitalization of 3,123.65 million, with net sales of 2,503.90 million and a net profit of -1,124.20 million over the latest four quarters. Shareholder's funds are 2,934.80 million, and total assets amount to 5,450.70 million.